<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">ACM</journal-id><journal-title-group><journal-title>Advances in Clinical Medicine</journal-title></journal-title-group><issn pub-type="epub">2161-8712</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/ACM.2020.108234</article-id><article-id pub-id-type="publisher-id">ACM-36938</article-id><article-categories><subj-group subj-group-type="heading"><subject>ACM20200800000_18639091.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  Tomita评分及修正版Tokuhashi评分标准在脊柱转移癌中的应用评价及影响转移癌预后的危险因素分析
  Evaluation of Tomita Score and Modified Tokuhashi Score in Spinal Metastasis and Analysis of Risk Factors Influencing Prognosis of Metastatic Carcinoma
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>杨</surname><given-names>斌</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>宋</surname><given-names>克亮</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>孙</surname><given-names>祥琛</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>岳</surname><given-names>斌</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff2"><addr-line>青岛大学附属医院骨肿瘤科，山东 青岛</addr-line></aff><aff id="aff3"><addr-line>青岛大学附属医院骨肿瘤科，山东 青岛 </addr-line></aff><aff id="aff1"><addr-line>null</addr-line></aff><pub-date pub-type="epub"><day>05</day><month>08</month><year>2020</year></pub-date><volume>10</volume><issue>08</issue><fpage>1566</fpage><lpage>1572</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  
    目的：探讨Tomita评分及修正版Tokuhashi评分标准在脊柱转移癌中的应用评价及其影响转移癌预后的危险因素分析。方法：对116例在我院行手术治疗的脊柱转移癌患者的生存期进行随访，平均年龄52.78岁，平均随访20个月(6~49个月)，记录患者中位生存期及总生存期，采用中位生存时间及其95%可信区间(CI)，用log-rank检验进行中位生存期分析；采用Kaplan-Meier曲线进行生存期分析。结果：116例患者术后中位生存期为17.36个月，修正版Tokuhashi评分系统患者的中位生存期为17个月，OS为19.32个月，Tomita评分系统的中位生存期为16个月，OS为16个月，两者都提供了具有统计学意义的结果。结论：Tomita评分系统和修正版Tokuhashi评分系统能有效判断患者的预后，单因素分析显示：年龄、性别、原发肿瘤的位置及生长速度、术前运动状态都可影响患者生存期。而对于肿瘤在脊柱转移的部位与手术方式可能对于生存期没有影响。
    Objective: To evaluate the application of Tomita score and modified Tokuhashi score in spinal metastasis and to analyze risk factors influencing prognosis of metastatic carcinoma. Methods: 116 patients with spinal metastases were followed up, the average age was 52.78 years old, the average follow-up was 20 months (6~49 months). The median survival time and total survival time were recorded. The median survival time and 95% confidence interval (CI) were used. The log rank test was used to analyze the median survival time. The Kaplan-Meier curve was used to analyze the survival time. Results: The median survival time of 116 patients was 17.36 months, that of the modified Tokuhashi scoring system was 17 months, that of the OS was 19.32 months, that of the Tomita scoring system was 16 months, and that of the OS was 16 months, both of which provided statistically significant results. Conclusion: Tomita scoring system and modified Tokuhashi scoring system can effectively judge the prognosis of patients. Single factor analysis shows that: age, gender, location and growth speed of primary tumor, and preoperative movement state can affect the survival period of patients. However, the site and operation mode of spinal metastasis may not affect the survival. 
  
 
</p></abstract><kwd-group><kwd>脊柱转移癌，Tomita评分系统，修正版Tokuhashi评分系统，中位生存期，总生存期，危险因素分析, Spinal Metastasis</kwd><kwd> Tomita Scoring System</kwd><kwd> Modified Tokuhashi Scoring System</kwd><kwd> Median Survival</kwd><kwd> Total Survival</kwd><kwd> Risk Factor Analysis</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>Tomita评分及修正版Tokuhashi评分标准在脊柱转移癌中的应用评价及影响转移癌预后的危险因素分析<sup> </sup></title><p>杨斌，宋克亮，孙祥琛，岳斌</p><p>青岛大学附属医院骨肿瘤科，山东 青岛</p><p>收稿日期：2020年7月18日；录用日期：2020年8月3日；发布日期：2020年8月10日</p><disp-formula id="hanspub.36938-formula48"><graphic xlink:href="//html.hanspub.org/file/5-1571463x5_hanspub.png"  xlink:type="simple"/></disp-formula></sec><sec id="s2"><title>摘 要</title><p>目的：探讨Tomita评分及修正版Tokuhashi评分标准在脊柱转移癌中的应用评价及其影响转移癌预后的危险因素分析。方法：对116例在我院行手术治疗的脊柱转移癌患者的生存期进行随访，平均年龄52.78岁，平均随访20个月(6~49个月)，记录患者中位生存期及总生存期，采用中位生存时间及其95%可信区间(CI)，用log-rank检验进行中位生存期分析；采用Kaplan-Meier曲线进行生存期分析。结果：116例患者术后中位生存期为17.36个月，修正版Tokuhashi评分系统患者的中位生存期为17个月，OS为19.32个月，Tomita评分系统的中位生存期为16个月，OS为16个月，两者都提供了具有统计学意义的结果。结论：Tomita评分系统和修正版Tokuhashi评分系统能有效判断患者的预后，单因素分析显示：年龄、性别、原发肿瘤的位置及生长速度、术前运动状态都可影响患者生存期。而对于肿瘤在脊柱转移的部位与手术方式可能对于生存期没有影响。</p><p>关键词 :脊柱转移癌，Tomita评分系统，修正版Tokuhashi评分系统，中位生存期，总生存期，危险因素分析</p><disp-formula id="hanspub.36938-formula49"><graphic xlink:href="//html.hanspub.org/file/5-1571463x6_hanspub.png"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2020 by author(s) and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY 4.0).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/5-1571463x7_hanspub.png" /> <img src="//html.hanspub.org/file/5-1571463x8_hanspub.png" /></p></sec><sec id="s3"><title>1. 前言</title><p>脊柱是癌症骨转移最常见的部位，随着医疗水平的提高，患者的预期寿命延长，超过70%的癌症患者在病情发展过程中会发生骨转移，通常会产生进行性的腰背痛，脊柱不稳，甚至发生病理性骨折，其中约20%的患者出现脊髓压迫症状，可导致感觉及运动功能出现障碍，大小便失禁甚至出现瘫痪，大约10%的患者接受了手术减压治疗，最主要的目的是缓解疼痛，恢复神经功能，加强脊柱稳定性，提高生活质量 [<xref ref-type="bibr" rid="hanspub.36938-ref1">1</xref>] [<xref ref-type="bibr" rid="hanspub.36938-ref2">2</xref>]。脊柱转移的症状发生是疾病发展的一个转折点，病人遭受剧烈疼痛及神经功能丧失的痛苦，然而随着肿瘤学的发展，特别是靶向治疗和免疫治疗的进展，患者生存率有所提高，从而推动了脊柱治疗方式的发展 [<xref ref-type="bibr" rid="hanspub.36938-ref3">3</xref>]，脊柱外科医生评估患者是否会从手术中获益需要考虑很多因素，其中最重要的是预测患者的生存时间。例如，预期寿命小于6个月的患者不适合进行手术，但他们可以从单独的放射治疗或支持性治疗中获得最大收益 [<xref ref-type="bibr" rid="hanspub.36938-ref4">4</xref>]。为了帮助临床医生便于决策，有几种评分系统可供使用并得到广泛应用，Tokuhashi评分由Tokuhashi等人于1990年出版，并于2005年修订，Tomita等人在2001年公布了他们的评分系统，而Bauer评分在1995年就已经开始了。在这些评分系统中，Tomita评分系统和修正版的Tokuhashi预后评分系统已经非常流行，并被用于确定患者的最佳治疗方案，然而这些系统在很多研究中被证明在预测患者生存期方面是有限的 [<xref ref-type="bibr" rid="hanspub.36938-ref5">5</xref>] [<xref ref-type="bibr" rid="hanspub.36938-ref6">6</xref>] [<xref ref-type="bibr" rid="hanspub.36938-ref7">7</xref>] [<xref ref-type="bibr" rid="hanspub.36938-ref8">8</xref>]。本研究的主要目的是评价Tomita评分系统(表1) [<xref ref-type="bibr" rid="hanspub.36938-ref9">9</xref>]、修正版Tokuhashi评分(表2) [<xref ref-type="bibr" rid="hanspub.36938-ref10">10</xref>] 系统在预测脊柱转移癌患者预后的有效性，同时探讨影响脊柱转移癌患者生存期的危险因素，为临床决策提供参考。</p></sec><sec id="s4"><title>2. 资料与方法</title><p>我们回顾性研究2012年至2018年间在我院接受手术治疗的122例脊柱转移患者的数据和结果，其中116例获得随访，其中男性75例，女性41例，患者平均年龄52.78岁，平均随访20个月(6~49个月)。该研究已获得青岛大学附属医院伦理委员会批准，所有患者均签署知情同意书。以患者术后至死亡或者失访为患者的总生存期OS，同时记录患者的中位生存期。术前采用Tomita评分标准及修正版Tokuhashi评分标准进行评价，患者术前及术后运动功能采用Frankel脊髓损伤分级评定，ABCD级为良好，E级为不良 [<xref ref-type="bibr" rid="hanspub.36938-ref11">11</xref>]。患者术前接受标准化的分期检查，包括平片透视、计算机断层扫描(CT)和矢状位重建，以及对整个脊柱进行磁共振成像(MRI)，以确定骨和内脏的受累范围和椎管受累情况。从病历中收集人口统计数据及医疗过程，通过电话随访或医院病历中获得患者生存数据。符合以下标准的患者被包括在内：1) 明确的脊柱转移癌病理诊断；2) 预期寿命大于3个月，内科难治性疼痛、神经功能迅速恶化、临床或者影像学检查有脊柱不稳定的证据；3) 患者自愿接受随访，有完整的临床资料或随访数据；符合以下情况的被排除在外：1) 单纯的椎体成形术；2) 预期寿命小于3个月；3) 淋巴瘤或多发性骨髓瘤等血液恶性肿瘤的患者；4) 拒绝接受随访或临床资料不完整的患者。</p><table-wrap id="table1" ><label><xref ref-type="table" rid="table1"><xref ref-type="table" rid="table">Table </xref>1</xref></label><caption><title> Tomita scores for metastatic carcinoma of the spin</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >大项</th><th align="center" valign="middle" >小项</th><th align="center" valign="middle" >分值</th></tr></thead><tr><td align="center" valign="middle"  rowspan="3"  >原发肿瘤位置及恶性程度</td><td align="center" valign="middle" >原发于乳腺、甲状腺、前列腺、睾丸等生长较慢的恶性肿瘤</td><td align="center" valign="middle" >1</td></tr><tr><td align="center" valign="middle" >原发于肾脏、子宫、卵巢、结直肠等生长较快的恶性肿瘤</td><td align="center" valign="middle" >2</td></tr><tr><td align="center" valign="middle" >原发于肺、胃、食管、鼻咽、肝、胰腺、膀胱、黑色素瘤、肉瘤(骨肉瘤、尤文肉瘤、平滑肌肉瘤等)等生长快的恶性肿瘤、其他少见的恶性肿瘤及原发灶不明者</td><td align="center" valign="middle" >4</td></tr><tr><td align="center" valign="middle"  rowspan="3"  >内脏转移情况</td><td align="center" valign="middle" >无内脏转移灶</td><td align="center" valign="middle" >0</td></tr><tr><td align="center" valign="middle" >有内脏转移灶可治疗</td><td align="center" valign="middle" >2</td></tr><tr><td align="center" valign="middle" >有内脏转移灶不可治疗者</td><td align="center" valign="middle" >4</td></tr><tr><td align="center" valign="middle"  rowspan="2"  >骨转移情况(以全身同位素骨扫描为准)</td><td align="center" valign="middle" >单发或孤立的脊柱转移灶</td><td align="center" valign="middle" >1</td></tr><tr><td align="center" valign="middle" >多发骨转移</td><td align="center" valign="middle" >2</td></tr></tbody></table></table-wrap><p>表1. 脊柱转移癌的Tomita评分</p><table-wrap-group id="2"><label><xref ref-type="table" rid="table2"><xref ref-type="table" rid="table">Table </xref>2</xref></label><caption><title> Tokuhashi prognostic score (revised version</title></caption><table-wrap id="2_1"><table><tbody><thead><tr><th align="center" valign="middle" >预测参数</th><th align="center" valign="middle" >分值</th></tr></thead><tr><td align="center" valign="middle" >全身情况(根据Karnofsky功能评分确定)</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >差</td><td align="center" valign="middle" >0</td></tr><tr><td align="center" valign="middle" >中等</td><td align="center" valign="middle" >1</td></tr><tr><td align="center" valign="middle" >良好</td><td align="center" valign="middle" >2</td></tr></tbody></table></table-wrap><table-wrap id="2_2"><table><tbody><thead><tr><th align="center" valign="middle" >脊柱外骨转移灶数量</th><th align="center" valign="middle" ></th></tr></thead><tr><td align="center" valign="middle" >≥3</td><td align="center" valign="middle" >0</td></tr><tr><td align="center" valign="middle" >1~2</td><td align="center" valign="middle" >1</td></tr><tr><td align="center" valign="middle" >0</td><td align="center" valign="middle" >2</td></tr><tr><td align="center" valign="middle" >主要脏器转移</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >不能切除</td><td align="center" valign="middle" >0</td></tr><tr><td align="center" valign="middle" >可以切除</td><td align="center" valign="middle" >1</td></tr><tr><td align="center" valign="middle" >无转移</td><td align="center" valign="middle" >2</td></tr><tr><td align="center" valign="middle" >原发肿瘤部位</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >肺、胃肠道、食道、膀胱和胰腺</td><td align="center" valign="middle" >0</td></tr><tr><td align="center" valign="middle" >肝、胆囊、原发灶不明</td><td align="center" valign="middle" >1</td></tr><tr><td align="center" valign="middle" >淋巴、结肠、卵巢和尿道</td><td align="center" valign="middle" >2</td></tr><tr><td align="center" valign="middle" >肾脏、子宫</td><td align="center" valign="middle" >3</td></tr><tr><td align="center" valign="middle" >直肠</td><td align="center" valign="middle" >4</td></tr><tr><td align="center" valign="middle" >甲状腺、乳腺、前列腺</td><td align="center" valign="middle" >5</td></tr><tr><td align="center" valign="middle" >受累椎体数量</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >≥3</td><td align="center" valign="middle" >0</td></tr><tr><td align="center" valign="middle" >2</td><td align="center" valign="middle" >1</td></tr><tr><td align="center" valign="middle" >1</td><td align="center" valign="middle" >2</td></tr><tr><td align="center" valign="middle" >瘫痪情况(根据Frankel神经功能分级情况确定)</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >完全瘫(Frankel A, B)</td><td align="center" valign="middle" >0</td></tr><tr><td align="center" valign="middle" >不全瘫(Frankel C, D)</td><td align="center" valign="middle" >1</td></tr><tr><td align="center" valign="middle" >无瘫痪 (Frankel E)</td><td align="center" valign="middle" >2</td></tr></tbody></table></table-wrap></table-wrap-group><p>表2. Tokuhashi预后评分法(修正版)</p></sec><sec id="s5"><title>3. 统计分析</title><p>数据采用SPSS22.0进行统计学分析。由于生存数据分布不均，采用中位生存时间及其95%可信区间(CI)，用log-rank检验进行中位生存期分析。生存曲线用Kaplan-Meier法进行生存期分析。P值 &lt; 0.050被认为具有统计学意义。</p></sec><sec id="s6"><title>4. 结果</title><p>通过对116例脊柱转移癌患者进行回顾性研究，男性75例，女性41例，转移灶位于颈椎、胸椎、腰椎、以及骶尾椎，其中颈椎21例、胸椎47例、胸腰椎12例，腰椎30例、骶尾椎2例，另外4例患者累及多个区域。其中最常见的原发恶性肿瘤为肺癌(42例)和乳腺癌(30例)，6例患者原发病灶尚不明确(表3)。手术方式分为：前入路椎板减压术12例，前入路椎板减压融合内固定术9例，后入路椎板减压术53例，后入路椎板减压内固定术42例 。116例患者术后中位生存期为17.36个月，95%可信区间为11.92~20.15个月。修正版Tokuhashi评分系统患者的中位生存期为17个月，95%可信区间为12.36~21.63个月，OS为19.32个月，95%可信区间为16.65~21.86个月，Tomita评分系统患者的中位生存期为16个月，95%可信区间为10.96~21.03个月，OS为16个月，95%可信区间为10.96~21.03个月，两者都提供了具有统计学意义的结果(表4)。另外，通过术前对影响生存期的单因素分析显示：年龄、性别、原发肿瘤的位置及生长速度、术前运动状态与术后生存时间有显著的统计学关系，较年轻、术前运动状态较好、原发病灶的生长速度较慢的患者可能会延长术后生存期。而肿瘤在脊柱转移的部位与手术方式可能对于患者术后生存期没有明显影响(表5)。</p><table-wrap id="table3" ><label><xref ref-type="table" rid="table3"><xref ref-type="table" rid="table">Table </xref>3</xref></label><caption><title> <xref ref-type="table" rid="table">Table </xref>of primary tumor sites diagnosed before surger</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >原发部位</th><th align="center" valign="middle" >数量</th><th align="center" valign="middle" >比例%</th></tr></thead><tr><td align="center" valign="middle" >肺</td><td align="center" valign="middle" >42</td><td align="center" valign="middle" >36.21</td></tr><tr><td align="center" valign="middle" >乳腺</td><td align="center" valign="middle" >30</td><td align="center" valign="middle" >25.86</td></tr><tr><td align="center" valign="middle" >肾</td><td align="center" valign="middle" >14</td><td align="center" valign="middle" >12.07</td></tr><tr><td align="center" valign="middle" >前列腺</td><td align="center" valign="middle" >12</td><td align="center" valign="middle" >10.34</td></tr><tr><td align="center" valign="middle" >结直肠</td><td align="center" valign="middle" >5</td><td align="center" valign="middle" >4.31</td></tr><tr><td align="center" valign="middle" >甲状腺</td><td align="center" valign="middle" >4</td><td align="center" valign="middle" >3.45</td></tr><tr><td align="center" valign="middle" >其他部位</td><td align="center" valign="middle" >3</td><td align="center" valign="middle" >2.59</td></tr><tr><td align="center" valign="middle" >原发部位不明确</td><td align="center" valign="middle" >6</td><td align="center" valign="middle" >5.17</td></tr></tbody></table></table-wrap><p>表3. 术前诊断的肿瘤原发部位表</p><table-wrap id="table4" ><label><xref ref-type="table" rid="table">Table </xref>4</label><caption><title> Survival analysis for each scoring syste</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >评分系统 (预测生存时间)</th><th align="center" valign="middle" >得分</th><th align="center" valign="middle" >中位生存期(95%可信区间)</th><th align="center" valign="middle" >OS (95%可信区间)</th><th align="center" valign="middle" >P</th></tr></thead><tr><td align="center" valign="middle" >Tokuhashi</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >&lt;6个月</td><td align="center" valign="middle" >0~8</td><td align="center" valign="middle" >10 (8.62~12.36)</td><td align="center" valign="middle" >12.60 (9.66~16.32)</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >6~11个月</td><td align="center" valign="middle" >9~11</td><td align="center" valign="middle" >26 (22.68~30.26)</td><td align="center" valign="middle" >30.18 (26.35~35.21)</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >&gt;1年</td><td align="center" valign="middle" >12~15</td><td align="center" valign="middle" >16 (12.36~19.62)</td><td align="center" valign="middle" >18.36 (16.16~20.46)</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >总计</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >17 (12.36~21.63)</td><td align="center" valign="middle" >19.32 (16.65~21.86)</td><td align="center" valign="middle" >0.003</td></tr><tr><td align="center" valign="middle" >Tomita</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >≥2年</td><td align="center" valign="middle" >2~3</td><td align="center" valign="middle" >36 (26.12~45.68)</td><td align="center" valign="middle" >38.24 (26.36~49.84)</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >1~2年</td><td align="center" valign="middle" >4~5</td><td align="center" valign="middle" >16 (10.36~21..42)</td><td align="center" valign="middle" >12.52 (9.28~15.68)</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >6~12个月</td><td align="center" valign="middle" >6~7</td><td align="center" valign="middle" >13 (8.42~17.52)</td><td align="center" valign="middle" >14.22 (9.52~18.88)</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >&lt;6个月</td><td align="center" valign="middle" >8~10</td><td align="center" valign="middle" >4 (2.36~5.69)</td><td align="center" valign="middle" >5.62 (3.52~7.68)</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >总计</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >16 (10.96‑21.03)</td><td align="center" valign="middle" >18.43 (14.18‑22.59)</td><td align="center" valign="middle" >0.001</td></tr></tbody></table></table-wrap><p>表4. 每种评分系统的生存期分析</p><table-wrap id="table5" ><label><xref ref-type="table" rid="table">Table </xref>5</label><caption><title> Single factor analysis before spinal metastatic carcinom</title></caption><table><tbody><thead><tr><th align="center" valign="middle"  colspan="2"  >影响因素</th><th align="center" valign="middle" >病例数</th><th align="center" valign="middle" >中位生存期/月</th><th align="center" valign="middle" >x2</th><th align="center" valign="middle" >p</th></tr></thead><tr><td align="center" valign="middle"  rowspan="2"  >性别</td><td align="center" valign="middle" >男</td><td align="center" valign="middle" >75</td><td align="center" valign="middle" >15.26</td><td align="center" valign="middle"  rowspan="2"  >9.356</td><td align="center" valign="middle"  rowspan="2"  >0.032</td></tr><tr><td align="center" valign="middle" >女</td><td align="center" valign="middle" >41</td><td align="center" valign="middle" >18.73</td></tr><tr><td align="center" valign="middle"  rowspan="2"  >年龄</td><td align="center" valign="middle" >≥50岁</td><td align="center" valign="middle" >67</td><td align="center" valign="middle" >16.35</td><td align="center" valign="middle"  rowspan="2"  >9.312</td><td align="center" valign="middle"  rowspan="2"  >0.026</td></tr><tr><td align="center" valign="middle" >&lt;50岁</td><td align="center" valign="middle" >49</td><td align="center" valign="middle" >20.12</td></tr><tr><td align="center" valign="middle"  rowspan="5"  >受累椎体位置</td><td align="center" valign="middle" >颈椎</td><td align="center" valign="middle" >21</td><td align="center" valign="middle" >19.25</td><td align="center" valign="middle"  rowspan="5"  >3.226</td><td align="center" valign="middle"  rowspan="5"  >0.312</td></tr><tr><td align="center" valign="middle" >胸椎</td><td align="center" valign="middle" >47</td><td align="center" valign="middle" >18.36</td></tr><tr><td align="center" valign="middle" >胸椎和腰椎</td><td align="center" valign="middle" >12</td><td align="center" valign="middle" >13.65</td></tr><tr><td align="center" valign="middle" >腰椎</td><td align="center" valign="middle" >30</td><td align="center" valign="middle" >23.68</td></tr><tr><td align="center" valign="middle" >骶尾椎</td><td align="center" valign="middle" >2</td><td align="center" valign="middle" >11.36</td></tr><tr><td align="center" valign="middle"  rowspan="2"  >术前运动功能</td><td align="center" valign="middle" >良好</td><td align="center" valign="middle" >74</td><td align="center" valign="middle" >22.36</td><td align="center" valign="middle"  rowspan="2"  >8.665</td><td align="center" valign="middle"  rowspan="2"  >0.023</td></tr><tr><td align="center" valign="middle" >不良</td><td align="center" valign="middle" >42</td><td align="center" valign="middle" >13.24</td></tr><tr><td align="center" valign="middle"  rowspan="3"  >原发肿瘤</td><td align="center" valign="middle" >慢速</td><td align="center" valign="middle" >37</td><td align="center" valign="middle" >21.63</td><td align="center" valign="middle"  rowspan="3"  >14.665</td><td align="center" valign="middle"  rowspan="3"  >0.006</td></tr><tr><td align="center" valign="middle" >中速</td><td align="center" valign="middle" >14</td><td align="center" valign="middle" >16.25</td></tr><tr><td align="center" valign="middle" >快速</td><td align="center" valign="middle" >65</td><td align="center" valign="middle" >10.35</td></tr><tr><td align="center" valign="middle" >手术方式</td><td align="center" valign="middle" >前入路椎板减压术</td><td align="center" valign="middle" >12</td><td align="center" valign="middle" >18.69</td><td align="center" valign="middle"  rowspan="4"  >1.258</td><td align="center" valign="middle"  rowspan="4"  >0.836</td></tr><tr><td align="center" valign="middle"  rowspan="3"  >05</td><td align="center" valign="middle" >前入路椎板减压融合内固定术</td><td align="center" valign="middle" >9</td><td align="center" valign="middle" >20.32</td></tr><tr><td align="center" valign="middle" >后入路椎板减压术</td><td align="center" valign="middle" >53</td><td align="center" valign="middle" >15.24</td></tr><tr><td align="center" valign="middle" >后入路椎板减压内固定术</td><td align="center" valign="middle" >42</td><td align="center" valign="middle" >26.38</td></tr></tbody></table></table-wrap><p>表5. 脊柱转移癌术前单因素分析</p></sec><sec id="s7"><title>5. 讨论</title><p>如今，癌症的个性化治疗已经进入了肿瘤学的领域，随着肿瘤学的发展，癌症患者的生存时间明显延长 [<xref ref-type="bibr" rid="hanspub.36938-ref12">12</xref>]。手术治疗的主要目的主要是缓解疼痛，恢复神经功能，加强脊柱稳定性，提高生活质量。脊柱转移瘤手术多为姑息性治疗，仅有极少数患者可进行肿瘤的广泛切除，但多数研究均显示选择性手术治疗可显著改善患者的生存质量，延长生存期 [<xref ref-type="bibr" rid="hanspub.36938-ref13">13</xref>]。生存期较短、功能预后差的患者可能不应该接受手术治疗，更适合支持治疗，比如放疗、化疗、靶向及免疫治疗，避免承受巨大的手术创伤及经济困难。相比之下，生存期较长、功能预后较好的患者可能从手术中获益更大，在选择最佳治疗方式之前，相对准确地预测患者的生存期是必要的，因此许多脊柱外科医生和放射科医生致力于发展一些有价值的评分系统，如Tokuhashi，Tomita，Vander Linden和Enkaoua [<xref ref-type="bibr" rid="hanspub.36938-ref9">9</xref>] [<xref ref-type="bibr" rid="hanspub.36938-ref10">10</xref>] [<xref ref-type="bibr" rid="hanspub.36938-ref14">14</xref>] [<xref ref-type="bibr" rid="hanspub.36938-ref15">15</xref>]，但是这些评分系统被证明都有一定的局限性，它们在预测不同患者的生存率时使用了相同的预后因素，但是拥有不同术前特征的患者可能对预后有不同的影响。</p><p>Tomita及修正版Tokuhashi评分标准现在已被广泛接受，并被用于确定最佳的治疗方案 [<xref ref-type="bibr" rid="hanspub.36938-ref16">16</xref>]。我们的研究显示它们在预测患者生存期方面都有显著的统计学意义。Tomita评分标准主要包含3个临床变量用于脊柱转移患者的术前预测，但不包括患者的一般情况和神经功能状态，而我们的研究显示患者术前的神经功能状态与预后有显著联系，术前神经功能状态越好，生存期越长。尽管这些评分都非常有帮助，然而随着治疗方式的多样化，仍然很难确定完全统一的标准来指导患者的临床治疗。</p><p>本次研究为单中心回顾性研究，病例数较少，结果准确性有待验证，需要多中心、大样本结果进行验证。</p></sec><sec id="s8"><title>文章引用</title><p>杨 斌,宋克亮,孙祥琛,岳 斌. Tomita评分及修正版Tokuhashi评分标准在脊柱转移癌中的应用评价及影响转移癌预后的危险因素分析Evaluation of Tomita Score and Modified Tokuhashi Score in Spinal Metastasis and Analysis of Risk Factors Influencing Prognosis of Metastatic Carcinoma[J]. 临床医学进展, 2020, 10(08): 1566-1572. https://doi.org/10.12677/ACM.2020.108234</p></sec><sec id="s9"><title>参考文献</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.36938-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Choi, D., Crockard, A., Bunger, C., Harms, J., Kawahara, N., Mazel, C., Melcher, R. and Tomita, K. (2010) Review of Metastatic Spine Tumour Classification and Indications for Surgery: The Consensus Statement of the Global Spine Tumour Study Group. European Spine Journal, 19, 215-222. &lt;br&gt;https://doi.org/10.1007/s00586-009-1252-x</mixed-citation></ref><ref id="hanspub.36938-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Choi, D., Bilsky, M., Fehlings, M., Fisher, C. and Gokaslan, Z. (2017) Spine Oncology-Metastatic Spine Tumors. Neurosurgery, 80, S131-S137. &lt;br&gt;https://doi.org/10.1093/neuros/nyw084</mixed-citation></ref><ref id="hanspub.36938-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Chamberlain, M.C., Sloan, A., Vrionis, F. and Cancer Care Ontario Practice Guidelines Initiative’s Neuro-Oncology Disease Site Group (2005) Systematic Review of the Diagnosis and Management of Malignant Extradural Spine Cord Compression: The Cancer Care Ontario Practice Guidelines Initiative’s Neuro-Oncology Disease Site Group. Journal of Clinical Oncology, 23, 7750-7751. &lt;br&gt;https://doi.org/10.1200/JCO.2005.02.7029</mixed-citation></ref><ref id="hanspub.36938-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Aoude, A. and Amiot, L. (2014) A Comparison of the Modified Tokuhashi and Tomita Scores in Determining Prognosis for Patients Afflicted with Spinal Metastasis. Canadian Journal of Surgery, 57, 188-193.  
&lt;br&gt;https://doi.org/10.1503/cjs.012013</mixed-citation></ref><ref id="hanspub.36938-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Ulmar, B., Naumann, U., Catalkaya, S., et al. (2007) Prognosis Scores of Tokuhashi and Tomita for Patients with Spinal Metastases of Renal Cancer. Annals of Surgical Oncology, 14, 998-1004.  
&lt;br&gt;https://doi.org/10.1245/s10434-006-9000-5</mixed-citation></ref><ref id="hanspub.36938-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Chen, H., Xiao, J., Yang, X., Zhang, F. and Yuan, W. (2010) Preoperative Scoring Systems and Prognostic Factors for Patients with Spinal Metastases from Hepato-Cellular Carcinoma. Spine (Phila Pa 1976), 35, E1339-E1346.  
&lt;br&gt;https://doi.org/10.1097/BRS.0b013e3181e574f5</mixed-citation></ref><ref id="hanspub.36938-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Gakhar, H., Swamy, G.N., Bommireddy, R., Calthorpe, D. and Klezl, Z. (2013) A Study Investigating the Validity of Modiﬁed Tokuhashi Score to Decide Surgical Intervention in Patients with Metastatic Spinal Cancer. European Spine Journal, 22, 565-568. &lt;br&gt;https://doi.org/10.1007/s00586-012-2480-z</mixed-citation></ref><ref id="hanspub.36938-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Quraishi, N.A., Manoharan, S.R., Arealis, G., et al. (2013) Accuracy of the Revised Tokuhashi Score in Predicting Survival in Patients with Metastatic Spinal Cord Compression (MSCC). European Spine Journal, 22, S21-S26.  
&lt;br&gt;https://doi.org/10.1007/s00586-012-2649-5</mixed-citation></ref><ref id="hanspub.36938-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Tomita, K., Kawahara, N., Kobayashi, T., et al. (2001) Surgical Strategy for Spinal Metastases. Spine (Phila Pa 1976), 26, 298-306. &lt;br&gt;https://doi.org/10.1097/00007632-200102010-00016</mixed-citation></ref><ref id="hanspub.36938-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Tokuhashi, Y., Matsuzaki, H., Oda, H., et al. (2005) A Revised Scoring System for Preoperative Evaluation of Metastatic Spine Tumor Prognosis. Spine (Phila Pa 1976), 30, 2186-2219.  
&lt;br&gt;https://doi.org/10.1097/01.brs.0000180401.06919.a5</mixed-citation></ref><ref id="hanspub.36938-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Kawahara, N., Tomita, K., Hisatoshi, B., et al. (2010) Total En Bloc Spondylectomy of the Lower Lumbar Spine: A Surgical Techniques of Combined Posterior-Anterior Approach. Spine, 36, 74-82.  
&lt;br&gt;https://doi.org/10.1097/BRS.0b013e3181cded6c</mixed-citation></ref><ref id="hanspub.36938-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Allemani, C., Matsuda, T., Di Carlo, V., et al. (2018) Global Surveillance of Trends in Cancer Survival 2000-14 (CONCORD-3): Analysis of Individual Records for 37513025 Patients Diagnosed with One of 18 Cancers from 322 Population-Based Registries in 71 Countries. The Lancet (London, England), 391, 1023-1075.  
&lt;br&gt;https://doi.org/10.1016/S0140-6736(17)33326-3</mixed-citation></ref><ref id="hanspub.36938-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Kim, J.M., Losina, E., Bono, C.M., et al. (2012) Clinical Outcome of Metastatic Spinal Cord Compression Treated with Surgical Excision Radiation versus Radiation Therapy Alone: A Systematic Review of Literature. Spine, 37, 78-84. &lt;br&gt;https://doi.org/10.1097/BRS.0b013e318223b9b6</mixed-citation></ref><ref id="hanspub.36938-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">Van der Linden, Y.M., Dijkstra, S.P., Vonk, E.J., Marijnen, C.A., Leer, J.W. and Dutch Bone Metastasis Study Group (2005) Prediction of Survival in Patients with Metastases in the Spinal Column. Results Based on a Randomized Trial of Radiotherapy. Cancer, 103, 320-328. &lt;br&gt;https://doi.org/10.1002/cncr.20756</mixed-citation></ref><ref id="hanspub.36938-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">Enkaoua, E.A., Doursounian, L., Chatellier, G., Mabesoone, F., Aimard, T. and Saillant, G. (1997) Vertebral Metastases: A Critical Appreciation of the Preoperative Prognostic Tokuhashi Score in a Series of 71 Cases. Spine (Phila Pa 1976), 22, 2293-2298. &lt;br&gt;https://doi.org/10.1097/00007632-199710010-00020</mixed-citation></ref><ref id="hanspub.36938-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">Leithner, A., Radl, R., Gruber, G., et al. (2008) Predictive Value of Seven Preoperative Prognostic Scoring Systems for Spinal Metastases. European Spine Journal, 17, 1488-1495. &lt;br&gt;https://doi.org/10.1007/s00586-008-0763-1</mixed-citation></ref></ref-list></back></article>